Life sciences business OptiBiotix Health plc (AIM: OPTI) on Wednesday announced the publication of a new peer-reviewed study on its functional ingredient SlimBiome in the European Journal of Nutrition, a high-impact international journal. The study supports SlimBiome as a science-backed, non-pharmaceutical approach to appetite regulation and weight management.

Conducted as a double-blind, placebo-controlled trial by Professor Adele Costabile of the University of Roehampton, the study found a single 3g dose of SlimBiome significantly reduced insulin levels, hunger and desire to eat, while increasing satiety. These results reinforce findings from prior clinical and consumer studies demonstrating SlimBiome's ability to reduce food intake and support sustained weight control.

The research was conducted to underpin health claims in support of a leading US weight management brand, with findings scheduled for presentation at the 18th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health from 24-26 June 2025.

OptiBiotix has built a robust body of evidence around SlimBiome, including both acute and long-term studies across healthy, overweight and obese populations. These studies have enabled the company to secure regulatory health claims in key markets including Europe, North America, Asia and Australia, supporting product launches with partners such as Morepen, Muscletech and Myprotein.

As anti-obesity drugs reshape the weight management sector, OptiBiotix is positioned to meet rising demand for science-driven, functional products targeting hunger control and appetite regulation.